KPTI - Karyopharm Therapeutics Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Newton,
United States
Type: Equity
KPTI price evolution
KPTI
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $53.19 | $44.58 | $81.85 | $85.54 |
| Short term investments | $139.21 | $164.66 | $155.87 | $176.32 |
| Net receivables | $26.96 | $37.92 | $32.28 | $35.2 |
| Inventory | $3.04 | $3.1 | $3.67 | $3.83 |
| Total current assets | $233.92 | $263.22 | $291.38 | $318.54 |
| Long term investments | ||||
| Property, plant & equipment | $4.88 | $5.48 | $6.06 | $6.63 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $6.52 | $6.74 | $6.45 | $7.26 |
| Total investments | $139.21 | $164.66 | $155.87 | $176.32 |
| Total assets | $240.44 | $269.96 | $297.83 | $325.8 |
| Current liabilities | ||||
| Accounts payable | $3.12 | $0.94 | $2.29 | $9.04 |
| Deferred revenue | ||||
| Short long term debt | $3.31 | $3.19 | $3.08 | $2.98 |
| Total current liabilities | $69.48 | $62.08 | $58.93 | $61.55 |
| Long term debt | $173.71 | $174.37 | $175 | $175.62 |
| Total noncurrent liabilities | $307.17 | $308.28 | $310.15 | $309.42 |
| Total debt | $177.02 | $177.56 | $178.08 | $178.59 |
| Total liabilities | $376.64 | $370.36 | $369.08 | $370.97 |
| Shareholders' equity | ||||
| Retained earnings | -$1487.04 | -$1445.2 | -$1410.69 | -$1378.07 |
| Other shareholder equity | -$0.16 | -$0.74 | -$0.78 | -$0.42 |
| Total shareholder equity | -$136.21 | -$100.4 | -$71.25 | -$45.17 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $53.19 | $136.88 | $197.44 | $89.12 |
| Short term investments | $139.21 | $142.78 | $38.16 | $163.32 |
| Net receivables | $26.96 | $47.09 | $22.5 | $12.88 |
| Inventory | $3.04 | $4.22 | $4.11 | $2.64 |
| Total current assets | $233.92 | $350.16 | $275.61 | $276.53 |
| Long term investments | $24.21 | |||
| Property, plant & equipment | $4.88 | $7.38 | $9.56 | $11.58 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $6.52 | $8.01 | $29.7 | $36.52 |
| Total investments | $139.21 | $142.78 | $38.16 | $187.54 |
| Total assets | $240.44 | $358.17 | $305.31 | $313.05 |
| Current liabilities | ||||
| Accounts payable | $3.12 | $2.77 | $1.6 | $4.45 |
| Deferred revenue | $0.3 | |||
| Short long term debt | $3.31 | $2.87 | $2.32 | $1.92 |
| Total current liabilities | $69.48 | $65.91 | $73.72 | $60.2 |
| Long term debt | $173.71 | $302.82 | $178.26 | $129.21 |
| Total noncurrent liabilities | $307.17 | $308.92 | $311.26 | $202.3 |
| Total debt | $177.02 | $179.07 | $180.58 | $131.13 |
| Total liabilities | $376.64 | $374.83 | $384.98 | $262.5 |
| Shareholders' equity | ||||
| Retained earnings | -$1487.04 | -$1343.94 | -$1178.65 | -$1069.61 |
| Other shareholder equity | -$0.16 | -$0.64 | $0.19 | $0.52 |
| Total shareholder equity | -$136.21 | -$16.66 | -$79.67 | $50.55 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $33.75 | $36.01 | $37.58 | $38.7 |
| Cost of revenue | $1.49 | $0.91 | $1.19 | $1.35 |
| Gross Profit | $32.26 | $35.1 | $36.38 | $37.35 |
| Operating activities | ||||
| Research & development | $39.38 | $35.55 | $31.48 | $32.34 |
| Selling, general & administrative | $30.69 | $30.8 | $34.48 | $35.91 |
| Total operating expenses | $70.07 | $66.36 | $65.96 | $68.25 |
| Operating income | -$37.81 | -$31.26 | -$29.57 | -$30.9 |
| Income from continuing operations | ||||
| EBIT | -$35.5 | -$28.42 | -$26.72 | -$28.31 |
| Income tax expense | $0.13 | $0.01 | $0.13 | $0.05 |
| Interest expense | $6.21 | $6.07 | $5.78 | $5.76 |
| Net income | ||||
| Net income | -$41.84 | -$34.51 | -$32.63 | -$34.13 |
| Income (for common shares) | -$41.84 | -$34.51 | -$32.63 | -$34.13 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $146.03 | $157.07 | $108.08 | |
| Cost of revenue | $4.94 | $5.21 | $2.71 | |
| Gross Profit | $141.09 | $151.86 | $105.38 | |
| Operating activities | ||||
| Research & development | $138.75 | $148.66 | $150.81 | |
| Selling, general & administrative | $131.88 | $145.4 | $126.42 | |
| Total operating expenses | $270.63 | $294.06 | $277.23 | |
| Operating income | -$129.54 | -$142.2 | -$171.85 | |
| Income from continuing operations | ||||
| EBIT | -$118.95 | -$139.93 | -$168.82 | |
| Income tax expense | $0.32 | $0.37 | $0.31 | |
| Interest expense | $23.82 | $25 | $27.14 | |
| Net income | ||||
| Net income | -$143.1 | -$165.29 | -$196.27 | |
| Income (for common shares) | -$143.1 | -$165.29 | -$196.27 | |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$41.84 | -$34.51 | -$32.63 | -$34.13 |
| Operating activities | ||||
| Depreciation | $0.08 | $0.08 | $0.08 | $0.29 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.18 | $5.08 | $6.06 | $5.39 |
| Total cash flows from operations | -$18.59 | -$29.53 | -$25.7 | -$18.91 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $26.84 | -$7.68 | $21.17 | -$32.39 |
| Total cash flows from investing | $26.84 | -$7.68 | $21.17 | -$32.39 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.26 | $0.86 | ||
| Net borrowings | ||||
| Total cash flows from financing | $0.26 | $0.86 | ||
| Effect of exchange rate | $0.09 | -$0.05 | -$0.03 | -$0.04 |
| Change in cash and equivalents | $8.61 | -$37.27 | -$3.69 | -$51.34 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$143.1 | -$165.29 | -$124.09 | -$196.27 |
| Operating activities | ||||
| Depreciation | $0.53 | $0.62 | $0.79 | $0.97 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $21.71 | $35.4 | $29.78 | $24.41 |
| Total cash flows from operations | -$92.72 | -$149.55 | -$107.12 | -$160.23 |
| Investing activities | ||||
| Capital expenditures | -$0.12 | -$0.21 | -$0.14 | |
| Investments | $7.94 | -$104.14 | $147.55 | -$53.54 |
| Total cash flows from investing | $7.94 | -$104.26 | $141.84 | -$53.69 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.12 | $193.74 | $13.65 | $172.08 |
| Net borrowings | $60 | |||
| Total cash flows from financing | $1.12 | $193.74 | $73.65 | $172.08 |
| Effect of exchange rate | -$0.03 | -$0.49 | -$0.05 | $0.27 |
| Change in cash and equivalents | -$83.69 | -$60.56 | $108.32 | -$41.57 |
News
Fundamentals
| Market cap | $125.26M |
|---|---|
| Enterprise value | $249.08M |
| Shares outstanding | 114.92M |
| Revenue | $146.03M |
|---|---|
| EBITDA | -$118.42M |
| EBIT | -$118.95M |
| Net Income | -$143.10M |
| Revenue Q/Q | 0.50% |
| Revenue Y/Y | -7.03% |
| P/E ratio | -0.88 |
|---|---|
| EV/Sales | 1.71 |
| EV/EBITDA | -2.10 |
| EV/EBIT | -2.09 |
| P/S ratio | 0.86 |
| P/B ratio | -0.92 |
| Book/Share | -1.18 |
| Cash/Share | 0.46 |
| EPS | -$1.25 |
|---|---|
| ROA | -50.47% |
| ROE | 162.14% |
| Debt/Equity | -2.77 |
|---|---|
| Net debt/EBITDA | -2.73 |
| Current ratio | 3.37 |
| Quick ratio | 3.32 |